The Ensysce delivery platform for large biomolcules is utilizing single walled carbon nanotubes (SWCNT) to produce intravenously delivered immunology and gene therapy products. The SWCNT platform that has demonstrated ability to transfect circulating T-cells following intravenous administration.  Ensyse is working to produce an IV product to deliver the highly novel immune and gene therapies being developed today.  We are exploring partnerships with others in the field to aid delivery of their products.